Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Somatogen (SMTG) -- Ignore unavailable to you. Want to Upgrade?

To: kha vu who wrote (429)	3/2/1998 6:44:00 AM
From: Madharry	Respond to of 442

This deal has to be approved by the shareholders. The board IMHO has prove itself over time to be useless in protecting the interest of shareholders. I am sure that when we get the full terms of the deal we will find that Somatogen Senior Management are kept on and offered golden parachutes and that the board is also treated very well, as far as the shareholders who bought at the initial offering of $24 or those that bought at the secondary of $17-oops! I haven't heard any of the usual " the company has hired investment bankers to explore other alternatives" . Personally, I think the deal is ludicrously cheap. After all SMTG has something like $3 in cash. So I am voting no.